136 results about "Glucose control" patented technology

The embodiment of the invention discloses a blood glucose index evaluation method, electronic equipment and a storage medium, and the method comprises the steps: obtaining the corresponding heart rate data of a target user in an evaluation time period, carrying out the feature extraction processing of the heart rate data, obtaining the corresponding target heart rate feature of the target user in the evaluation time period, and obtaining the target heart rate feature of the target user in the evaluation time period; inputting the target heart rate feature and a target calibration parameter corresponding to the target user into a blood glucose evaluation model, and predicting blood glucose control index data corresponding to the target user in the evaluation time period through the blood glucose evaluation model. The target heart rate features and the target calibration parameters are used as input of a blood glucose evaluation model, and the blood glucose management and control index data of the target user in the evaluation time period are predicted through the blood glucose evaluation model, so that it is ensured that the obtained heart rate data corresponding to the target user in the evaluation time period are utilized; and the accuracy of the blood glucose management and control index data corresponding to the target user in the evaluation time period is determined, and meanwhile, the cost of blood glucose monitoring is greatly reduced.

The invention discloses a training method of a blood glucose control model and a blood glucose control method and system, and belongs to the technical field of blood glucose control. According to the method, a framework combining a blood glucose control model and a reinforcement learning model is constructed; wherein the blood glucose control model is a full-connection neural network with two layers; the number of neurons in the first layer of the network is 3, and an adopted activation function is a linear function; the number of neurons in the second layer of the network is 1, the adopted activation function is a nonlinear activation function, the output value domain of the nonlinear activation function is bounded, the upper bound is a positive number, and the lower bound is a negative number. The blood glucose control model is a model evolved after a classic PID algorithm is improved based on a blood glucose control task, the parameter space of the model comprises the parameter space of the classic PID algorithm, and the model has a wider range, can extract features with higher expression ability, is more adaptive to a reinforcement learning process, and can simply and efficiently realize accurate control of blood glucose.

The present invention discloses modified-release bilayer tablets consisting of two layers, layer 1 consisting 500 mg sustained release metformin and layer 2 consisting 250 mg normal release metformin and 5mg / 10mg delayed-release dapagliflozin. This formulation is meticulously designed to regulate blood glucose levels effectively over an extended period. Immediate-release metformin swiftly addresses acute glucose spikes, while sustained-release metformin ensures prolonged glucose control, minimizing fluctuations throughout the day. The delayed-release dapagliflozin component allows for controlled and timed release, managing persistent hyperglycemia synergistically with metformin. By optimizing efficacy and minimizing glucose fluctuations, this innovative formulation offers a promising solution for stable glycemic control in individuals with diabetes. Present invention aims to improve patient outcomes and enhance overall quality of life by maintaining stable glucose levels and reducing the risk of complications associated with uncontrolled diabetes.

According to one embodiment of the present disclosure, provided is a method for assisting blood glucose control of a subject using a computer system, the method comprising: acquiring a target set by the subject; acquiring a GA value of the subject; generating a GA value trend using the plurality of GA values; outputting a GA value trend to the object person; and outputting the target set by the subject to the subject.

The present invention provides a method for improving glycemic control in a patient in need thereof, comprising administering to said patient, tirzepatide, or a pharmaceutically acceptable salt thereof, wherein said patient has failed to reach their HbA1c goal using GLP-1 RA treatment. The present invention provides a method for improving weight management in a patient in need thereof, comprising administering to said patient tirzepatide, or a pharmaceutically acceptable salt thereof, wherein said patient has failed to reach their weight management goal using GLP-1 RA treatment.

The invention relates to the field of intelligent medical monitoring, in particular to a diabetic multi-source data real-time analysis method based on a large language model, and the method mainly comprises the steps: continuously collecting multi-source data of a patient from a CGM device, an intelligent watch and a mobile terminal, and enabling the multi-source data to at least comprise blood glucose data, heart rate and input data; constructing a deep learning model comprising four layers of attention mechanisms, inputting the fusion data into the deep learning model, predicting a blood glucose trend within a preset time by using a sliding time window to obtain a blood glucose prediction result, and pushing the blood glucose prediction result to the mobile terminal or the smart watch; and performing reinforcement learning on the large language model based on a deep Q network architecture, and when the blood glucose control time in the blood glucose data is lower than a preset threshold value, performing parameter updating on the large language model. According to the invention, personalized monitoring and intervention effects on the diabetic patient can be improved.

A diabetes management system optimizes glucoregulatory hormone delivery using a connected glucoregulatory hormone delivery system and a computing device with a processor and non-transitory memory. The system receives glucose management data (glucose, insulin delivery, heart rate, or carbohydrate consumption data) from sensors. A digital twin metabolic model is selected and initialized based on the received data. The system simulates diabetes treatment interventions to predict glucose dynamics and determines an optimized glucoregulatory hormone parameter (e.g., insulin dose or increment that minimizes hyperglycemia and hypoglycemia risk). The determined glucoregulatory hormone parameter is transmitted to the connected glucoregulatory hormone delivery system, which may include an automated insulin delivery (AID) system or a connected insulin pen system, for implementation. By integrating real-time physiological data with predictive metabolic modeling, the system enhances glucoregulatory hormone therapy, providing personalized adjustments to improve glucose control.

Provided herein are methods for improving glycemic control in a human patient, methods for treating, preventing or reducing overweight or obesity and related co-conditions, and methods for treating or preventing type II diabetes mellitus by administering a polypeptide to the patient, the polypeptide comprises a fibronectin type III tenth (10Fn3) domain that binds to a myostatin. In some embodiments, the polypeptides are administered according to a specific clinical dosing regimen (e.g., at a specific dose and according to a specific time interval) (or for administration according to the regimen).

The invention discloses application of a fucoidin degradation product Fuc-S in a pharmaceutical composition for preventing, relieving or treating type 2 diabetes mellitus and liver injury, and relates to the technical field of biological medicines. The invention provides a new effect of fucoidin Fuc-S in treating diabetic liver injury, and particularly, the fucoidin Fuc-S can significantly improve blood glucose control (reducing fasting blood glucose and enhancing sugar tolerance) and blood lipid spectrum (reducing TG, TC and LDL-C and increasing HDL-C) of diabetic mice, alleviate liver fatty degeneration and reduce serum ALT / AST level, and shows a significant liver protection effect. Furthermore, the Fuc-S can be used for remodeling the intestinal flora structure through specific enrichment of beneficial bacteria such as Bacteroides acdifaciens and the like, so that the generation of short-chain fatty acid (SCFAs) with a liver protection effect is promoted. The flora and metabolic change jointly improve the oxidative stress state of the liver, inhibit pro-inflammatory response and reduce lipid accumulation. The invention provides a novel nutrition intervention strategy for prevention and treatment of T2DM and liver complications thereof.

The present disclosure relates to a method of preventing or treating a disease or disorder in a subject in need thereof, wherein administration of a composition of the present disclosure is effective to result in an increase of energy expenditure in the subject. The present disclosure provides a method of reducing fat mass and / or improving glycemic control in a subject in need thereof. The present disclosure provides a method of promoting weight loss and weight maintenance. The present disclosure provides a method of maintaining lean mass. Compositions for use in the methods include a compound of formula (I), (II), or (III), or pharmaceutically acceptable salts thereof, or in combination with a compound selected from the group consisting of an ACC2 inhibitor and an incretin mimetic.

The present invention provides a method of increasing glycemic control in a patient in need thereof by administering tizatide, or a pharmaceutically acceptable salt thereof. The present invention provides a method of improving body weight management in a patient in need thereof by administering tizatide, or a pharmaceutically acceptable salt thereof. Also provided is a method of treating a condition selected from the group consisting of atherosclerosis, chronic kidney disease, NAFLD and NASH. Also provided is a method of preventing or causing alleviation of diabetes mellitus, comprising administering tizatide or a pharmaceutically acceptable salt thereof. Also provided is a dosing regimen for increasing glycemic control, improving weight management, and / or treating dyslipidemia.

The invention provides a specific full-nutrient formula food applied to diet-restricted diabetes mellitus groups, and belongs to the technical field of formula foods for special medical purposes. According to the product, marine active substances and medicinal and edible traditional Chinese medicine extracts are innovatively compounded, and a multi-probiotic microencapsulation technology is combined, so that a specific full-nutrition formula with the functions of regulating blood sugar, improving insulin resistance and protecting target organ functions is formed. The formula comprises marine active ingredients such as marine collagen tripeptide, a sea cucumber saponin extract and fucoidan as well as medicinal and edible traditional Chinese medicine extracts such as mulberry leaves, rhizoma polygonati and radix puerariae, and oligopeptide, amino acid, multivitamins and mineral substances in a specific proportion are matched. Probiotics are protected by adopting a three-layer microencapsulation technology to pass through a gastric acid environment, active ingredients are reserved by utilizing a low-temperature enzymolysis and molecular directed extraction technology, and the nutritional status and blood sugar control of diabetic patients can be remarkably improved through clinical verification. The product conforms to the GB 29922-2013 special medical purpose formula food standard, can be used as a single nutrition source for diabetics, and meets the special nutrition requirements of the diabetics.

A medical device and method for determining a basal dose of insulin and a bolus dose of insulin to be administered for glycemic control is provided. The medical device includes an insulin pump, a control interface including a button configured to select one of a plurality of present bolus insulin doses based on input from a user (e.g., a patient), and a controller configured for executing instructions to determine a basal insulin delivery rate based, at least in part, on a total daily basal insulin dose and to determine the plurality of preset bolus insulin doses based, at least in part, on a total daily bolus insulin dose.

The invention provides curcumin-nano-selenium modified Chinese chestnut starch with an irregular granular porous network structure, and belongs to the technical field of starch processing. The preparation method comprises the following steps: mixing a sodium selenite solution and a curcumin solution, and reacting under an alkaline condition to obtain a curcumin-nano-selenium solution; carrying out heat-moisture treatment on the starch suspension, and then freeze-drying to obtain heat-treated starch; preparing the heat-treated starch into a suspension 1, mixing the suspension 1 with the curcumin-nano-selenium solution, performing a constant-temperature oscillation reaction under a dark condition, and after the reaction is finished, cooling and drying to obtain the modified starch. According to the invention, a spherical aggregate of natural starch is reconstructed into an irregular granular porous network structure, so that the freeze-thaw stability, retrogradation stability, oxidation resistance and digestion resistance of the starch are remarkably improved. Moreover, based on a mouse experiment result, the modified starch has a good blood sugar control effect.

Provided are a method, system, and computer-readable medium for optimizing glycemic control of a diabetic subject having Type 1 diabetes through co-administration of sodium-glucose cotransporter inhibitors (SGLTi) and insulin. Such co-administration can be effected by, for example, regulating one or more administration reactions in view of analyses of continuous glucose monitoring (CGM) data that can be indicative of at least the potential for one or more glycemic events including hypoglycemia and hyperglycemia. The aforementioned regulation can occur according to a balancing of insulin infusion and provisioning of SGLTi so as to avoid the occurrence of either of such events while, at the same time, not promoting an instance of diabetic ketoacidosis (DKA).

Provided are methods for treating glucose-related metabolic disorders in a subject. In some aspects, the methods comprise enterally administering an effective amount of a beta-glucan oligosaccharide prior to and / or during the subject consuming a glucose source.

The present application relates to the technical field of mRNA vaccine, and specifically discloses a proinsulin mRNA vaccine for protecting the function and quantity of pancreatic beta cells. The vaccine is composed of a lipid nanoparticle (LNP) and an mRNA wrapped by the LNP; the mRNA is an mRNA sequence encoding proinsulin, and all uridines in the mRNA sequence are replaced by N1-methyl pseudouridine. The mRNA vaccine of the present application realizes the dual protection of the quantity and function of pancreatic beta cells, compared with the existing intervention means which only focus on blood glucose control or immune regulation, the present application delays the occurrence process of type 1 diabetes from the root, and provides a new technical scheme and drug selection for the prevention and early intervention of type 1 diabetes.

The invention relates to the technical field of medical informatics, and provides a diabetic diet optimization recommendation system based on deep learning. According to the system, structural feature construction is conducted on blood glucose, diet and life behavior data, blood glucose response structural decoupling, meal anchoring and cross-day stability features are introduced, and fine description of individual postprandial blood glucose dynamic response is achieved; in the blood glucose response prediction process, a local Dirichlet energy constrained deep learning model is introduced to improve the stability and generalization consistency of a prediction result; and a joint distribution density reasoning mechanism is combined to enhance the robust processing capability of missing follow-up visit data. On the basis, an individualized diet optimization recommendation result is generated by introducing a reinforcement learning method, collaborative optimization of blood glucose control, nutrition balance and patient compliance is achieved, and reliable intelligent decision support is provided for diabetes mellitus follow-up visit management.

The application discloses a personalized closed-loop artificial pancreas system, which comprises a detection module (100) for continuously detecting blood glucose values of a patient, an infusion module (102) for infusing insulin into the patient, and a program module (101) for controlling the detection module (100) and the infusion module (102). The program module (101) generates insulin infusion instructions according to the blood glucose values detected by the detection module (100) and controls the infusion module (102) to perform infusion. The program module (101) comprises a user interface. In response to an input of the patient, the program module (101) executes a corresponding meal mode function. The meal mode comprises a high-carbohydrate mode and a normal-carbohydrate meal mode. According to the input of the patient, the program module (101) executes the function of the high-carbohydrate mode or the normal-carbohydrate mode, so as to be applicable to people with different carbohydrate consumption habits, improve the adaptability of the closed-loop artificial pancreas to different people, and enable people with different carbohydrate consumption habits to maintain a satisfactory blood glucose control effect.

The application discloses a breast reconstruction type recommendation system and method based on multi-modal data, relates to the technical field of breast reconstruction type recommendation, and aims to solve the technical problems of traditional operation type recommendation depending on linear superposition evaluation of a single index, being unable to quantize the nonlinear complex mechanism of metabolic and vascular injury, and leading to inaccurate risk evaluation and lack of targeted recommendation, the system comprising a feature calculation and analysis module, wherein the feature calculation and analysis module comprises a clinical information structured unit, a metabolic and vascular injury index calculation module, an image feature unit and a test feature unit. Through the metabolic and vascular injury index calculation module, the nonlinear normalization function, the standardization function, the interactive effect analysis algorithm and the Sigmoid function are integrated, the true risk difference between patients with short disease duration but poor blood glucose control and patients with long disease duration but good blood glucose control is effectively distinguished, the risk evaluation is more in line with the pathophysiological law, and a scientific quantitative basis is provided for operation type selection.

A personalized closed-loop infusion system and method. Relevant information of patients is uploaded to a cloud server (104), and is grouped on the basis of identifiable features of the patients; the relevant information of different patients, such as blood glucose data records and insulin infusion data records, is compared in a same group; and when the relevant information of the patients is the same or similar, insulin algorithm parameters of patients with well-controlled blood glucose can be used for modifying an insulin algorithm of patients with poorly-controlled blood glucose, and a closed-loop artificial pancreas system can quickly obtain personalized insulin algorithms suitable for the patients without the need of long-period learning of physiological characteristics and lifestyle habits of the patients, thereby benefiting diabetes treatment of the patients.

In at least one embodiment, a hemoglobin measuring device may include a plurality of sensors, a display configured to present information, and a computing device in communication with the sensors and display and having a processor and a memory storing instructions executable by the processor. The instructions may include instructions to receive, from the sensors, measurements of one or more forms of glycated hemoglobin in a blood samples, determine a total fetal hemoglobin value in the blood sample by performing a peak area summation of all forms of fetal hemoglobin, subtract the total fetal hemoglobin value from 100 to derive a total adult hemoglobin value, determine a glycated fetal hemoglobin value, compare the glycated fetal hemoglobin value to a reference range to obtain a comparison, determine a baseline glucose control value based on the comparison, and output the baseline glucose control value and the comparison to a display for medical evaluation.

This invention relates to fusion proteins comprising an insulin receptor agonist fused to the Fc region of human IgG2, and the use of such fusion proteins in the treatment of diabetes. The fusion proteins of this invention have a prolonged duration of action and can be used to provide extended periods of basal glucose control.

To provide protective agents with excellent effects such as starch retrogradation inhibition, prevention or inhibition of the decrease in activity of proteins during storage in a frozen or freeze-dried state, prevention or inhibition of damage or death of microorganisms during storage in a frozen or freeze-dried state, and pH buffering; surfactants with excellent surfactant properties; blood glucose control compositions that do not raise blood glucose levels when administered to individuals; autophagy inducers with excellent autophagy induction properties; staining agents for acid-fast bacteria that can easily and efficiently stain acid-fast bacteria; and protein extractants with excellent protein extraction properties. [Solution] A protective agent, surfactant composition, blood glucose control composition, autophagy inducer, acid-fast bacilli staining agent, or protein extractant characterized by containing a compound represented by general formula (1).

This invention belongs to the field of biomedical technology and discloses the application of NP in the preparation of a glycemic regulator for aging type 2 diabetes. The NP is a nanoscale complex formed by hydrogen bonding of turtle egg peptide with a molecular weight less than 3 kDa and naringenin at a mass ratio of 100:1. The formulation promotes liver glycogen synthesis and repairs pancreatic tissue structure and pancreatic β-cell function by activating the hepatic IRS1 / PI3K / AKT / GSK-3β signaling pathway and upregulating GLUT2 protein expression. The NP provided by this invention can significantly reduce fasting blood glucose levels in aging type 2 diabetic mice, improve oral glucose tolerance, and reduce the area under the blood glucose curve. Simultaneously, by restoring insulin signal transduction, it significantly reduces the insulin resistance index and improves the insulin sensitivity index, with an improvement level approaching that of the classic hypoglycemic drug metformin.

The present invention recognizes that, there is a need for the prophylaxis or treatment of obesity, glycemic control, and other metabolic disorders. A first aspect of the present invention generally relates to methods of prophylaxis or treatment of obesity, glycemic control, and other metabolic disorders, using various pharmaceutical compositions. A second aspect of the present invention generally relates to mono-therapy or combination therapy used for the prophylaxis or treatment of obesity, glycemic controh other metabolic disorders, and combinations thereof

To provide a closed-loop blood glucose control system and method.SOLUTION: A control device (30) for determining a recommendation value of a control parameter of an insulin infusion device (20).SELECTED DRAWING: Figure 1

Provided is a wearable medical device that includes a processor or logic circuitry. The wearable medical device may include a memory storing instructions that, when executed by the processor or logic circuitry, configure the wearable medical device to determine, by the processor or the logic circuitry, that an event affecting a blood glucose measurement value trend of a user has occurred. Based on the occurrence of the event, the processor or the logic circuitry may select a mode of operation of the analyte sensor, and generate a signal indicating the selected mode of operation. The mode of operation may correspond to a sampling frequency of a physical attribute or physiological condition of a user of the wearable medical device.